Pyoderma gangrenosum-like necrotizing panniculitis associated with Imatinib: A case report
https://doi.org/10.4081/dr.2020.8381
Accepted: 20 June 2020
HTML: 157
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Imatinib mesylate is a small tyrosine kinase inhibitor that targets BCR-ABL, ckit and platelet-derived growth factor receptor. It is prescribed by hematologists for chronic myeloid leukemia and acute lymphoblastic leukemia and by oncologists for Gastrointestinal Stromal Tumors (GIST). Cutaneous reactions to Imatinib are common but their incidence and severity widely varies between patients. A self-limited skin rash is the most common adverse effect but there have been reported cases of patients with maculopapular rash, pigmentary changes, superficial edema and rarer and clinically distinctive features such as lichenoid reactions or psoriasis. We here describe for the first time a case of pyoderma gangrenosum–like necrotizing panniculitis, a rare dermatological condition, after initiating therapy with Imatinib.
2. Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): Diagnosis and management. Dermatol Ther. 2010;23(4):320–7.
3. Hatipoğlu U, Stoller JK. α1-Antitrypsin Deficiency. Clin Chest Med [Internet]. 2016 Sep;37(3):487–504. Available from: https://linkinghub.elsevier.com/retrieve/pii/S027252311630048X
4. Lyon MJ. Metabolic panniculitis: Alpha-1 antitrypsin deficiency panniculitis and pancreatic panniculitis. Dermatol Ther. 2010;23(4):368–74.
5. Vigl K, Monshi B, Vujic I, Rappersberger K. Pyoderma gangrenosum-like necrotizing panniculitis associated with alpha-1 antitrypsin deficiency: a lethal course. JDDG J der Dtsch Dermatologischen Gesellschaft [Internet]. 2015 Nov;13(11):1180–4. Available from: http://doi.wiley.com/10.1111/ddg.12830
6. Napier RJ, Norris BA, Swimm A, Giver CR, Harris WAC, Laval J, et al. Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity. PLoS Pathog. 2015;11(3):1–27.
7. Vrekoussis Vrekoussis T, Stathopoulos EN, De Giorgi U, Kafousi M, Pavlaki K, Kalogeraki A, et al. Modulation of Vascular Endothelium by Imatinib: A Study on the EA.hy 926 Endothelial Cell Line. J Chemother. 2014;18(1):56–65.
8. Sharma R, Pinato D. Imatinib induced pyoderma gangrenosum. J Postgrad Med [Internet]. 2013;59(3):244. Available from: http://www.jpgmonline.com/text.asp?2013/59/3/244/118059
9. Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2017;177(1):72–83.
10. Lopez Pineiro M, Willis E, Yao C, Chon SY. Pyoderma gangrenosum–like ulceration of the lower extremity secondary to sunitinib therapy: a case report. SAGE Open Med Case Reports [Internet]. 2018 Jan 18;6:2050313X1878304. Available from: http://journals.sagepub.com/doi/10.1177/2050313X18783048
11. Zaki S. Adverse drug reaction and causality assessment scales. Lung India [Internet]. 2011;28(2):152. Available from: http://www.lungindia.com/text.asp?2011/28/2/152/80343
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
